These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2545 related articles for article (PubMed ID: 19095124)

  • 41. Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance.
    Villers A; Lemaitre L; Haffner J; Puech P
    Curr Opin Urol; 2009 May; 19(3):274-82. PubMed ID: 19325494
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Association between serum triiodothyronine (t3) level and risk of disease recurrence in men with localized prostate cancer.
    Lehrer S; Diamond EJ; Bajwa AM; Kornreich R; Stagger S; Stone NN; Droller MJ; Stock RG
    Prostate Cancer Prostatic Dis; 2001; 4(4):232-234. PubMed ID: 12497024
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The contemporary concept of significant versus insignificant prostate cancer.
    Ploussard G; Epstein JI; Montironi R; Carroll PR; Wirth M; Grimm MO; Bjartell AS; Montorsi F; Freedland SJ; Erbersdobler A; van der Kwast TH
    Eur Urol; 2011 Aug; 60(2):291-303. PubMed ID: 21601982
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Radiotherapy combined with hormonal therapy (RT-HT) in prostate cancer patients with low, intermediate, and high risk of biochemical recurrence: perspective and therapeutic gain analysis.
    Milecki P; Kwias Z; Martenka DJ
    Neoplasma; 2007; 54(1):7-15. PubMed ID: 17203887
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nerve-sparing focal cryoablation of prostate cancer.
    Polascik TJ; Mayes JM; Mouraviev V
    Curr Opin Urol; 2009 Mar; 19(2):182-7. PubMed ID: 19188772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Biopsy schemes with the fewest cores for detecting 95% of the prostate cancers detected by a 24-core biopsy.
    Scattoni V; Raber M; Abdollah F; Roscigno M; Dehò F; Angiolilli D; Maccagnano C; Gallina A; Capitanio U; Freschi M; Doglioni C; Rigatti P; Montorsi F
    Eur Urol; 2010 Jan; 57(1):1-8. PubMed ID: 19720449
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prostate saturation biopsy in the reevaluation of microfocal prostate cancer.
    Boccon-Gibod LM; de Longchamps NB; Toublanc M; Boccon-Gibod LA; Ravery V
    J Urol; 2006 Sep; 176(3):961-3; discussion 963-4. PubMed ID: 16890668
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer.
    Naito S; Kuroiwa K; Kinukawa N; Goto K; Koga H; Ogawa O; Murai M; Shiraishi T;
    J Urol; 2008 Sep; 180(3):904-9; discussion 909-10. PubMed ID: 18635221
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Active surveillance with selective delayed intervention for favorable risk prostate cancer.
    Klotz L
    Urol Oncol; 2006; 24(1):46-50. PubMed ID: 16414494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy--can we predict adverse pathological outcomes?
    Thong AE; Shikanov S; Katz MH; Gofrit ON; Eggener S; Zagaja GP; Shalhav AL; Zorn KC
    J Urol; 2008 Dec; 180(6):2436-40. PubMed ID: 18930486
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nomogram prediction for prostate cancer and aggressive prostate cancer at time of biopsy: utilizing all risk factors and tumor markers for prostate cancer.
    Nam RK; Toi A; Klotz LH; Trachtenberg J; Jewett MA; Loblaw A; Pond GR; Emami M; Sugar L; Sweet J; Narod SA
    Can J Urol; 2006 Apr; 13 Suppl 2():2-10. PubMed ID: 16672122
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
    Zackrisson B; Aus G; Bergdahl S; Lilja H; Lodding P; Pihl CG; Hugosson J
    J Urol; 2004 Apr; 171(4):1500-3. PubMed ID: 15017207
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men.
    Chun FK; Haese A; Ahyai SA; Walz J; Suardi N; Capitanio U; Graefen M; Erbersdobler A; Huland H; Karakiewicz PI
    Cancer; 2008 Aug; 113(4):701-9. PubMed ID: 18553365
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
    Thomas C; Wiesner C; Melchior S; Gillitzer R; Schmidt F; Thüroff JW
    J Urol; 2008 Nov; 180(5):1938-41; discussion 1941. PubMed ID: 18801501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
    Lane BR; Zippe CD; Abouassaly R; Schoenfield L; Magi-Galluzzi C; Jones JS
    J Urol; 2008 May; 179(5):1746-50; discussion 1750. PubMed ID: 18343412
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Patient selection for hemiablative focal therapy of prostate cancer: variables predictive of tumor unilaterality based upon radical prostatectomy.
    Polascik TJ; Mayes JM; Schroeck FR; Sun L; Madden JF; Moul JW; Mouraviev V
    Cancer; 2009 May; 115(10):2104-10. PubMed ID: 19288576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.
    Steyerberg EW; Roobol MJ; Kattan MW; van der Kwast TH; de Koning HJ; Schröder FH
    J Urol; 2007 Jan; 177(1):107-12; discussion 112. PubMed ID: 17162015
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 8q gain is an independent predictor of poor survival in diagnostic needle biopsies from prostate cancer suspects.
    Ribeiro FR; Jerónimo C; Henrique R; Fonseca D; Oliveira J; Lothe RA; Teixeira MR
    Clin Cancer Res; 2006 Jul; 12(13):3961-70. PubMed ID: 16818693
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prostate cancer detection rate in patients with repeated extended 21-sample needle biopsy.
    Campos-Fernandes JL; Bastien L; Nicolaiew N; Robert G; Terry S; Vacherot F; Salomon L; Allory Y; Vordos D; Hoznek A; Yiou R; Patard JJ; Abbou CC; de la Taille A
    Eur Urol; 2009 Mar; 55(3):600-6. PubMed ID: 18597923
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extended pattern prostate biopsy does not minimize the volume-grade bias in prostate cancer detection.
    Al-Ghamdi AM; Lockwood G; Toi A; Kulkarni GS; Evans A; Finelli A; Zlotta AR; Fleshner N
    J Urol; 2008 Apr; 179(4):1332-4. PubMed ID: 18289588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 128.